1. Home
  2. ACOG vs FATE Comparison

ACOG vs FATE Comparison

Compare ACOG & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$5.67

Market Cap

115.5M

Sector

N/A

ML Signal

HOLD

Logo Fate Therapeutics Inc.

FATE

Fate Therapeutics Inc.

HOLD

Current Price

$1.29

Market Cap

124.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACOG
FATE
Founded
2000
2007
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
115.5M
124.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
ACOG
FATE
Price
$5.67
$1.29
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$18.00
$3.92
AVG Volume (30 Days)
76.2K
1.7M
Earning Date
11-13-2025
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,427,199.00
$7,137,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$132.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.75
$0.66
52 Week High
$11.54
$1.94

Technical Indicators

Market Signals
Indicator
ACOG
FATE
Relative Strength Index (RSI) 42.26 64.97
Support Level $5.20 $1.02
Resistance Level $6.04 $1.22
Average True Range (ATR) 0.44 0.08
MACD -0.08 0.03
Stochastic Oscillator 28.02 91.43

Price Performance

Historical Comparison
ACOG
FATE

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Share on Social Networks: